Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRX-102 Dose-Ranging Study in Adult Fabry Patients
NCT01678898Phase 2Completed
- Sponsor
- Protalix BioTherapeutics
- Start
- Oct 2012
- Primary completion
- Mar 2016
- Modality
- PEGylated Peptides, Replacement Enzymes
- Countries
- 6
01
Overview
Phase 2, open-label trial of pegunigalsidase alfa in Fabry disease (FD) (3 arms), sponsored by Protalix BioTherapeutics. Primary endpoint: Adverse Events at 12 months. Started Oct 2012; status: completed.
02
Drugs
pegunigalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT01678898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01678898.